Frequently Asked Questions
The global chemiluminescence immunoassay (CLIA) market was valued at USD 6.1 Billion in 2022.
The chemiluminescence immunoassay (CLIA) market is expected to grow at a CAGR of 6.80% between 2023 and 2030, reaching USD 9.66 Billion in 2030.
Reagents are the leading segment by product type, holding around half of the share in value in 2022.
The endocrine disorders application segment governs the demand for chemiluminescence immunoassay (CLIA) worldwide, holding a massive share of nearly 45% in 2022.
The autoimmune disorder segment will post the highest CAGR during the forecast period.
North America is fueling the growth of the chemiluminescence immunoassay (CLIA) industry, with a nearly two-fifth share in 2022.
The top players include F. Hoffmann-La Roche AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Danaher (Beckman Coulter Inc.), DiaSorin S.p.A., Sysmex Corporation, Randox Laboratories Ltd., Tosoh Corporation, Shenzhen New Industries Biomedical Engineering Co., Ltd., BioMerieux and others.
The increasing prevalence of chronic and acute diseases is expected to drive the demand for chemiluminescence immunoassay (CLIA).
The industry needs more skilled professionals and strict government regulations restraint of chemiluminescence immunoassay (CLIA).
The increase in the use of chemiluminescence immunoassay in identifying chronic illnesses such as obesity, infectious diseases, diabetes, and autoimmune and cardiovascular diseases is an opportunity for Chemiluminescence Immunoassay (CLIA) in the industry.